OTC Sleep Aid Sales Snooze As Consumers Wake Up To Alternatives
This article was originally published in The Pink Sheet
Natural products cut into sales of OTC sleep aids as more consumers prefer naturals as non-addictive and not causing grogginess the following day, Kline & Co. research shows. OTC sleep aids posted 3.4% growth in 2016, down from 50% to 15% growth in recent years.
You may also be interested in...
Label Warnings Against Driving Start Arriving For OTC Sleep Ingredients In US
Unisom Sleeptab with 25 mg doxylamine is first OTC sleep remedy adding warning not to drive a vehicle or operate machinery and five others FDA requested in “changes being effected” letter. Agency’s ongoing review found “labeling deficiencies” with doxylamine and diphenhydramine.
Beauty Supplements Draw Young Adults, Disease Prevention Attracts All Ages
Most US women ages 18-34 who take a supplement do so for beauty benefits, finds Mintel in a survey. Natural Marketing Institute says with science increasing understanding of nutrients, firms should offer supplements that address symptoms of common conditions consumers are treating with drugs.
Merck Silence On OTC Singulair Speaks Volumes On Switch Outlook
Merck’s silence on an OTC version of Singulair is a sign of the relatively “quiet” 2015 switch market despite the call for novel switches, particularly to treat chronic conditions, from FDA’s Nonprescription Drug Safe Use Regulatory Expansion Initiative.